Document Detail


First-trimester ADAM12s as early markers of trisomy 21: a promise still unfulfilled?
MedLine Citation:
PMID:  18382998     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: Here we study the levels of ADAM12s prior to and after 10 weeks of gestation to establish further the effectiveness or otherwise of ADAM12s as an early screening marker. MATERIALS AND METHODS: Samples collected as part of routine first-trimester screening were retrieved from storage at - 80 degrees C. In total, 55 samples from pregnancies with trisomy 21 were identified, 31 collected between the 6th and 9th weeks of gestation and 24 collected after the 10th week. A series of 567 gestational age-matched samples collected during the same period formed the control group. RESULTS: The median, multiples of the median (MoM) ADAM12s, at a median gestation of 10.0 weeks was 0.66, which was significantly lower than in the controls (p = < 0.001) when compared by Mann-Whitney test. The median MoM in those cases (n = 31) collected prior to 10 weeks was 0.618 MoM at a median gestation of 9.1 weeks. In those collected prior to 9 weeks (n = 14) the median was 0.596 at a median gestation of 8.6 weeks. CONCLUSIONS: The data from this study does not support data from a previous study showing ultra-low levels of ADAM12s in pregnancies affected by trisomy 21 prior to 10 weeks of gestation.
Authors:
Kevin Spencer; Nicholas J Cowans; Niels Uldbjerg; Niels Tørring
Related Documents :
15672008 - Nuchal translucency and fetal cardiac defects: a pooled analysis of major fetal echocar...
7479598 - Prenatal diagnosis of trisomy 8 mosaicism in cvs after abnormal ultrasound findings at ...
19797008 - Prenatal sonographic features of fetuses in trisomy 13 pregnancies (i).
8863698 - Screening for trisomy 21 in twin pregnancies by maternal age and fetal nuchal transluce...
22933738 - Disease-modifying drugs for multiple sclerosis in pregnancy: a systematic review.
22009758 - Clinical course in women undergoing termination of pregnancy within the legal time limi...
Publication Detail:
Type:  Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Prenatal diagnosis     Volume:  28     ISSN:  0197-3851     ISO Abbreviation:  Prenat. Diagn.     Publication Date:  2008 Apr 
Date Detail:
Created Date:  2008-04-03     Completed Date:  2008-08-18     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8106540     Medline TA:  Prenat Diagn     Country:  England    
Other Details:
Languages:  eng     Pagination:  338-42     Citation Subset:  IM    
Copyright Information:
Copyright (c) 2008 John Wiley & Sons, Ltd.
Affiliation:
Prenatal Screening Unit, Department of Clinical Biochemistry, King George Hospital, Barley Lane, Goodmayes, Essex IG3 8YB, UK. KevinSpencer1@aol.com
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
ADAM Proteins / blood*
Adult
Biological Markers / blood
Down Syndrome / blood*,  diagnosis*
Early Diagnosis
Female
Gestational Age
Humans
Membrane Proteins / blood*
Pregnancy
Pregnancy Outcome
Pregnancy Trimester, First / blood*
Prenatal Diagnosis* / methods
Chemical
Reg. No./Substance:
0/Biological Markers; 0/Membrane Proteins; EC 3.4.24.-/ADAM 12 protein; EC 3.4.24.-/ADAM Proteins

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Structural heart defects associated with an increased nuchal translucency: 9 years experience in a r...
Next Document:  Preliminary results of fetal Rhc examination in plasma of pregnant women with anti-c.